• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纤连蛋白1(FN1)通过EDB区域的可变剪接塑造甲状腺乳头状癌的行为。

FN1 shapes the behavior of papillary thyroid carcinoma through alternative splicing of EDB region.

作者信息

Liu Mian, Chen Pei, Wei Bo, Tan Hai-Long, Zhao Ya-Xin, Ai Lei, Li Ning, Jiang Ying-Ke, Lin Jing, Li Shi-Jin, Chang Shi

机构信息

Department of General Surgery, XiangYa Hospital Central South University, No. 87 XiangYa Road, Changsha, 410008, Hunan, China.

National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Xiangya Road 87, Changsha, 410008, Hunan, China.

出版信息

Sci Rep. 2025 Jan 2;15(1):327. doi: 10.1038/s41598-024-83369-5.

DOI:10.1038/s41598-024-83369-5
PMID:39747903
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11695688/
Abstract

Papillary thyroid cancer (PTC) is often characterized by indolent behavior, small tumors with slow cell proliferation and a tendency to metastasize to cervical lymph node simultaneously, and the molecular mechanisms underlying that remain poorly understood. In this study, FN1 was the hottest gene of PTC and distinctive expression in PTC cells. FN1 deficiency severely inhibited the p53 signaling pathway, especially cyclin proteins, resulting in increased cell growth but hampered invasion. The alternatively splicing EDB region of FN1 was exclusively expressed in tumors, which impacted integrin β1 (ITGB1) bonding FN1 and its secretion process, resulting in completely distinct roles of two isoforms that FN1 including and skipping EDB domain. The isoform EDB(-)FN1 intracellularly inhibited tumor proliferation by upregulating p21 expression, whereas extracellular EDB(+)FN1 promoted lymph node metastasis via the VEGF signaling pathway in vitro and in vivo. Moreover, the alternative splicing EDB region of FN1 was modulated by p53-targeted protein ZMAT3 which activated cell migration and lymphoangiogenesis. Collectively, combined with p53-induced proteins, FN1 played both anti- and pro-cancer roles owing to EDB domain alternative splicing. FN1 is a potential determinant behind the characteristic behavior of PTC, which may contribute to a deeper understanding of the peculiarity of PTC and provide a promising target for regional lymph node metastasis.

摘要

甲状腺乳头状癌(PTC)通常具有惰性生物学行为,肿瘤较小,细胞增殖缓慢,且往往同时转移至颈部淋巴结,但其潜在的分子机制仍知之甚少。在本研究中,纤连蛋白1(FN1)是PTC中最热门的基因,在PTC细胞中呈特异性表达。FN1缺陷严重抑制p53信号通路,尤其是细胞周期蛋白,导致细胞生长增加但侵袭受阻。FN1的可变剪接EDB区域仅在肿瘤中表达,影响整合素β1(ITGB1)与FN1的结合及其分泌过程,导致包含和跳过EDB结构域的两种FN1亚型具有完全不同的作用。EDB(-)FN1亚型通过上调p21表达在细胞内抑制肿瘤增殖,而细胞外EDB(+)FN1在体外和体内通过VEGF信号通路促进淋巴结转移。此外,FN1的可变剪接EDB区域受p53靶向蛋白ZMAT3调控,ZMAT3激活细胞迁移和淋巴管生成。总体而言,与p53诱导的蛋白相结合,由于EDB结构域的可变剪接,FN1发挥了抗癌和促癌的双重作用。FN1是PTC特征性行为背后的一个潜在决定因素,这可能有助于更深入地理解PTC的特殊性,并为区域淋巴结转移提供一个有前景的靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeb7/11695688/3f6656fee5ac/41598_2024_83369_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeb7/11695688/77d09b294e0f/41598_2024_83369_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeb7/11695688/b3e2251cc0d8/41598_2024_83369_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeb7/11695688/d57748cb30f4/41598_2024_83369_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeb7/11695688/1b445916ebf7/41598_2024_83369_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeb7/11695688/0ccddb1355c7/41598_2024_83369_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeb7/11695688/3614fa3c7b42/41598_2024_83369_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeb7/11695688/7590ff42d336/41598_2024_83369_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeb7/11695688/69c2ecf910be/41598_2024_83369_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeb7/11695688/3f6656fee5ac/41598_2024_83369_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeb7/11695688/77d09b294e0f/41598_2024_83369_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeb7/11695688/b3e2251cc0d8/41598_2024_83369_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeb7/11695688/d57748cb30f4/41598_2024_83369_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeb7/11695688/1b445916ebf7/41598_2024_83369_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeb7/11695688/0ccddb1355c7/41598_2024_83369_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeb7/11695688/3614fa3c7b42/41598_2024_83369_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeb7/11695688/7590ff42d336/41598_2024_83369_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeb7/11695688/69c2ecf910be/41598_2024_83369_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeb7/11695688/3f6656fee5ac/41598_2024_83369_Fig9_HTML.jpg

相似文献

1
FN1 shapes the behavior of papillary thyroid carcinoma through alternative splicing of EDB region.纤连蛋白1(FN1)通过EDB区域的可变剪接塑造甲状腺乳头状癌的行为。
Sci Rep. 2025 Jan 2;15(1):327. doi: 10.1038/s41598-024-83369-5.
2
MicroRNA-142-3P suppresses the progression of papillary thyroid carcinoma by targeting FN1 and inactivating FAK/ERK/PI3K signaling.微小 RNA-142-3P 通过靶向 FN1 并使 FAK/ERK/PI3K 信号失活来抑制甲状腺乳头状癌的进展。
Cell Signal. 2023 Sep;109:110792. doi: 10.1016/j.cellsig.2023.110792. Epub 2023 Jul 3.
3
FBXO2 promotes the progression of papillary thyroid carcinoma through the p53 pathway.FBXO2 通过 p53 通路促进甲状腺乳头状癌的进展。
Sci Rep. 2024 Sep 29;14(1):22574. doi: 10.1038/s41598-024-73455-z.
4
A 5'-tRNA halve, tiRNA-Gly promotes cell proliferation and migration via binding to RBM17 and inducing alternative splicing in papillary thyroid cancer.一种5'-tRNA半体,即tiRNA-Gly,通过与RBM17结合并诱导甲状腺乳头状癌中的可变剪接来促进细胞增殖和迁移。
J Exp Clin Cancer Res. 2021 Jul 5;40(1):222. doi: 10.1186/s13046-021-02024-3.
5
ITGA3-MET interaction promotes papillary thyroid cancer progression via ERK and PI3K/AKT pathways.整合素α3(ITGA3)与肝细胞生长因子受体(MET)的相互作用通过细胞外信号调节激酶(ERK)和磷脂酰肌醇-3激酶/蛋白激酶B(PI3K/AKT)信号通路促进甲状腺乳头状癌进展。
Ann Med. 2025 Dec;57(1):2483379. doi: 10.1080/07853890.2025.2483379. Epub 2025 Mar 26.
6
The splicing factor QKI inhibits metastasis by modulating alternative splicing of E-Syt2 in papillary thyroid carcinoma.剪接因子 QKI 通过调节甲状腺乳头状癌中 E-Syt2 的可变剪接抑制转移。
Cancer Lett. 2024 Nov 1;604:217270. doi: 10.1016/j.canlet.2024.217270. Epub 2024 Sep 19.
7
miR-215 suppresses papillary thyroid cancer proliferation, migration, and invasion through the AKT/GSK-3β/Snail signaling by targeting ARFGEF1.miR-215 通过靶向 ARFGEF1 抑制 AKT/GSK-3β/Snail 信号通路抑制甲状腺乳头状癌细胞的增殖、迁移和侵袭。
Cell Death Dis. 2019 Feb 27;10(3):195. doi: 10.1038/s41419-019-1444-1.
8
Oncogenic Ras/squamous cell carcinoma antigen signaling pathway activation promotes invasiveness and lymph node metastases in papillary thyroid carcinoma.致癌性 Ras/鳞状细胞癌抗原信号通路的激活促进甲状腺乳头状癌的侵袭性和淋巴结转移。
Oncol Rep. 2019 Feb;41(2):1253-1263. doi: 10.3892/or.2018.6895. Epub 2018 Nov 28.
9
Xenotropic and polytropic retrovirus receptor 1 (XPR1) promotes progression of papillary thyroid carcinoma via the BRAF-ERK1/2-P53 signaling pathway.嗜异性和多嗜性逆转录病毒受体1(XPR1)通过BRAF-ERK1/2-P53信号通路促进甲状腺乳头状癌的进展。
J Endocrinol Invest. 2025 Mar;48(3):633-652. doi: 10.1007/s40618-024-02481-5. Epub 2024 Nov 2.
10
Regulates -Induced EMT Gene Transcription to Promote the Metastasis and Tumorigenesis of Papillary Thyroid Carcinoma.调控诱导 EMT 基因转录促进甲状腺乳头状癌的转移和肿瘤发生。
Discov Med. 2024 Sep;36(188):1819-1830. doi: 10.24976/Discov.Med.202436188.168.

本文引用的文献

1
Exercise-activated hepatic autophagy via the FN1-α5β1 integrin pathway drives metabolic benefits of exercise.运动激活的通过 FN1-α5β1 整合素途径的肝脏自噬驱动运动的代谢益处。
Cell Metab. 2023 Apr 4;35(4):620-632.e5. doi: 10.1016/j.cmet.2023.01.011. Epub 2023 Feb 21.
2
KEGG for taxonomy-based analysis of pathways and genomes.KEGG 用于基于分类的途径和基因组分析。
Nucleic Acids Res. 2023 Jan 6;51(D1):D587-D592. doi: 10.1093/nar/gkac963.
3
Targeted Contrast Agents for Magnetic Resonance Molecular Imaging of Cancer.靶向对比剂用于癌症的磁共振分子成像。
Acc Chem Res. 2022 Oct 4;55(19):2833-2847. doi: 10.1021/acs.accounts.2c00346. Epub 2022 Sep 19.
4
Cell cycle regulation: p53-p21-RB signaling.细胞周期调控:p53-p21-RB 信号通路。
Cell Death Differ. 2022 May;29(5):946-960. doi: 10.1038/s41418-022-00988-z. Epub 2022 Mar 31.
5
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
6
Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.下调 GRP78 通过 miR-495-3p 模拟物逆转三阴性乳腺癌的吡柔比星耐药性,涉及 p-AKT/mTOR 通路。
Biosci Rep. 2022 Jan 28;42(1). doi: 10.1042/BSR20210245.
7
Thyroid cancer incidence trends by histology in 25 countries: a population-based study.25 个国家基于人群的甲状腺癌发病率的组织学趋势研究。
Lancet Diabetes Endocrinol. 2021 Apr;9(4):225-234. doi: 10.1016/S2213-8587(21)00027-9. Epub 2021 Mar 1.
8
p53 and Tumor Suppression: It Takes a Network.p53 与肿瘤抑制:需要一个网络。
Trends Cell Biol. 2021 Apr;31(4):298-310. doi: 10.1016/j.tcb.2020.12.011. Epub 2021 Jan 28.
9
Antitumor Effects of CAR T Cells Redirected to the EDB Splice Variant of Fibronectin.针对纤连蛋白 EDB 剪接变异体的 CAR T 细胞的抗肿瘤作用。
Cancer Immunol Res. 2021 Mar;9(3):279-290. doi: 10.1158/2326-6066.CIR-20-0280. Epub 2020 Dec 22.
10
Current practice in patients with differentiated thyroid cancer.分化型甲状腺癌患者的现行治疗方法。
Nat Rev Endocrinol. 2021 Mar;17(3):176-188. doi: 10.1038/s41574-020-00448-z. Epub 2020 Dec 18.